A developing world strategy for personalized medicine

The following is an excerpt.

Because of its technology intensive platform, personalized medicine is seen as solely benefiting the populations of developed economies. Developing economies and health systems won’t have or won’t allocate the resources for adopting personalized medicines protocols. But for developing economies, the economics will play a crucial role in how it develops. Treatment protocols for smaller more specific populations might increase initial costs, but the targeted strategy should be more effective, more quickly and with fewer side effects. The benefit in a cost-benefit calculation would substantially increase — as would the efficacy of the treatment.

View the original article here: A Developing World Strategy for Personalized Medicines

Outbreak Daily Digest
Biotech Facts & Fallacies
Talking Biotech
Genetics Unzipped
Infographic: What are mRNA COVID-19 vaccines and how do they work?

Infographic: What are mRNA COVID-19 vaccines and how do they work?

As of 1 December 2020, thirteen vaccines have reached the final stage of testing: where they are being given to ...

Environmental Working Group: EWG challenges safety of GMOs, food pesticide residues

Known by some as the "Environmental Worrying Group," EWG lobbies ...
m hansen

Michael Hansen: Architect of Consumers Union ongoing anti-GMO campaign

Michael K. Hansen (born 1956) is thought by critics to be ...
News on human & agricultural genetics and biotechnology delivered to your inbox.
glp menu logo outlined

Newsletter Subscription

Optional. Mail on special occasions.
Send this to a friend